Science - 31 January 2020

(pbo) + chemo as neoadjuvant treatment, followed by pembro

vs pbo as adjuvant treatment for early triple-negative breast

cancer (TNBC).Ann. Oncol. 30 , v851–v934 (2019).

doi:10.1093/annonc/mdz394.003

78. M. Provencio-Pullaet al., Neoadjuvant chemo/
    immunotherapy for the treatment of stages IIIA
    resectable non-small cell lung cancer (NSCLC): A
    phase II multicenter exploratory study—NADIM
    study-SLCG.J. Clin. Oncol. 36 , 8521 (2018). doi:10.1200/
    JCO.2018.36.15_suppl.8521


79. T. M. Prowell, J. A. Beaver, R. Pazdur, Residual disease after
    neoadjuvant therapy—developing drugs for high-risk early
    breast cancer.N. Engl. J. Med. 380 , 612–615 (2019).
    doi:10.1056/NEJMp1900079; pmid: 30763188
    80.R.Sunet al., A radiomics approach to assess tumour-
    infiltrating CD8 cells and response to anti-PD-1 or
    anti-PD-L1 immunotherapy: An imaging biomarker,
    retrospective multicohort study.Lancet Oncol. 19 ,
    1180 – 1191 (2018). doi:10.1016/S1470-2045(18)30413-3;
    pmid: 30120041


80. S. Trebeschiet al., Predicting response to cancer
    immunotherapy using non-invasive radiomic biomarkers.
    Ann. Oncol. 30 , 998–1004 (2019). doi:10.1093/annonc/
    mdz108; pmid: 30895304
    82. M. N. McCracken, R. Tavaré, O. N. Witte, A. M. Wu, Advances
    in PET detection of the antitumor T cell response.Adv.
    Immunol. 131 , 187–231 (2016). doi:10.1016/bs.ai.2016.02.004;
    pmid: 27235684
    83. E. A. Eisenhaueret al., New response evaluation criteria in solid
    tumours: Revised RECIST guideline (version 1.1).Eur. J. Cancer
    45 , 228–247 (2009). doi:10.1016/j.ejca.2008.10.026;
    pmid: 19097774
    84. Y. Simoniet al., Bystander CD8+T cells are abundant and
    phenotypically distinct in human tumour infiltrates.Nature 557 ,
    575 – 579 (2018). doi:10.1038/s41586-018-0130-2;
    pmid: 29769722

ACKNOWLEDGMENTS

The authors thank L. Beswick (Johns Hopkins University School

of Medicine) for editorial assistance.Funding:We gratefully

acknowledge research support from NCI R01 CA142779 (to

S.L.T., J.M.T., and D.M.P.), the Cancer Research Institute/Stand

Up To Cancer-Immunology Translational Cancer Research Grant

AACR-DT1012 (to D.M.P.), Bristol-Myers Squibb (S.L.T., J.M.T.,

and D.M.P.), the Barney Family Foundation (S.L.T.), Moving for

Melanoma of Delaware (S.L.T.), the Laverna Hahn Charitable

Trust (S.L.T.), the Melanoma Research Alliance (J.M.T.), the

Harry J. Lloyd Charitable Trust (J.M.T.), the Emerson Collective

Foundation (J.M.T.), the Mark Foundation for Cancer Research

(J.M.T. and D.M.P.), and the Johns Hopkins Bloomberg-Kimmel

Institute for Cancer Immunotherapy (S.L.T., J.M.T., and D.M.P.).

Authors’contributions:All authors participated in the writing

and final approval of this article.Competing interests:D.M.P.

and S.L.T. report stock and other ownership interests from

Aduro Biotech, Compugen, DNAtrix, Dragonfly Therapeutics,

Ervaxx, Five Prime Therapeutics,FLX Bio, Jounce Therapeutics,

Potenza Therapeutics, Tizona Therapeutics, and WindMIL;

consulting or advisory role with AbbVie, Amgen, Bayer,

Compugen,DNAtrix,DragonflyTherapeutics,Dynavax,Ervaxx,

Five Prime Therapeutics, FLX Bio, Immunocore, lmmunomic

Therapeutics,JanssenOncology,Medlmmune,Merck,Tizona

Therapeutics, and Wind MIL; research funding from Bristol-Myers

Squibb, Compugen, and Potenza Therapeutics; patents, royalties,

and other intellectual property from Aduro Biotech, Bristol-Myers

Squibb, and lmmunonomic Therapeutics; and travel,

accommodations, and expenses from Bristol-Myers Squibb

and Five Prime Therapeutics. J.M.T. reports receiving equipment

and reagents from Akoya Biosciences; grants and personal

fees from Bristol-Myers Squibb; and personal fees from Merck,

Astra Zeneca, and Amgen.

10.1126/science.aax0182

Topalianet al.,Science 367 , eaax0182 (2020) 31 January 2020 9of9

RESEARCH | REVIEW